Crinetics Pharmaceuticals, Inc.
CRNX
$36.05
-$1.84-4.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4,208.39% | -86.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4,208.39% | -86.13% | |||
| Cost of Revenue | -4.79% | 590.62% | |||
| Gross Profit | 11.46% | -648.43% | |||
| SG&A Expenses | 2.74% | 4.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.03% | 9.67% | |||
| Operating Income | 6.26% | -10.44% | |||
| Income Before Tax | 5.73% | -12.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.59% | -12.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.59% | -12.50% | |||
| EBIT | 6.26% | -10.44% | |||
| EBITDA | 6.29% | -10.47% | |||
| EPS Basic | 6.47% | -12.00% | |||
| Normalized Basic EPS | 6.60% | -11.99% | |||
| EPS Diluted | 6.47% | -12.00% | |||
| Normalized Diluted EPS | 6.60% | -11.99% | |||
| Average Basic Shares Outstanding | 0.94% | 0.45% | |||
| Average Diluted Shares Outstanding | 0.94% | 0.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||